Immunologic Targets in AML

Blood Cancer Discov. 2023 Nov 1;4(6):430-432. doi: 10.1158/2643-3230.BCD-23-0161.

Abstract

In this issue of Blood Cancer Discovery, Nelde and colleagues used a sensitive mass spectrometry-based immunopeptidomics approach to characterize the antigenic landscape of acute myeloid leukemia (AML) and were able to identify immunogenic peptides presented by both leukemia stem cells (LSC) and bulk primary AML blasts. These immunogenic peptides elicit primarily CD4 T-cell responses and the diversity of the HLA class II immunopeptidome and presence of CD4 memory T-cell responses were both associated with improved clinical outcome. See related article by Nelde et al., p. 468 (1) .

Publication types

  • Comment

MeSH terms

  • CD4-Positive T-Lymphocytes
  • Humans
  • Leukemia, Myeloid, Acute*
  • Peptides

Substances

  • Peptides